IFRX InflaRx N.V. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1708688 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | 2025Q2*2025-06-30 | 2024Q2*2024-06-30 | 2023Q2*2023-06-30 | 2022Q2*2022-06-30 | 2021Q2*2021-06-30 | 2019Q2*2019-06-30 | 2018Q2*2018-06-30 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 39,432 | 6,357 | — | — | — | — | — |
| Cost of revenue | 2.40M | 348,153 | — | — | — | — | — |
| Gross profit | -2.36M | -341,796 | — | — | — | -16.14M | -8.19M |
| R&D expense | 7.20M | 10.02M | 10.92M | 11.18M | 11.30M | 12.50M | 5.03M |
| SG&A expense | 3.28M | 3.23M | 3.54M | 4.35M | 2.70M | 3.65M | 3.16M |
| Interest expense | 3,355 | 8,732 | 5,052 | 2,243 | 305 | 388,000 | 37,000 |
| Income tax | — | — | — | 0 | 0 | — | — |
| Net income | -14.42M | -13.85M | -8.20M | 465,376 | -14.78M | -15.27M | -2.44M |
| EPS (basic) | -0.21 | -0.24 | -0.14 | 0.01 | — | -0.59 | -0.10 |
| EPS (diluted) | -0.21 | -0.24 | -0.14 | 0.01 | -0.33 | -0.59 | -0.10 |
| Weighted avg. shares (diluted) | — | — | — | — | — | 25,964 | 24,890 |
| Banking | |||||||
| Net interest income | -323 | -2,056 | -363 | — | — | — | — |
| Balance sheet | |||||||
| Cash & equivalents | 13.00M | 19.15M | 19.52M | 15.42M | 72.36M | 54.06M | 156.07M |
| Receivables | — | 23,727 | — | — | — | — | — |
| Inventory | 5.04M | 9.64M | 578,705 | — | — | — | — |
| Current assets | 66.17M | 91.30M | 112.22M | 112.13M | — | 142.53M | — |
| PP&E, netmay include right-of-use assets (IFRS) | 247,027 | 272,446 | 296,382 | 231,133 | — | 1.64M | — |
| Intangibles | — | — | — | — | — | 453,000 | — |
| Total assets | 73.44M | 93.04M | 132.96M | 114.63M | — | 144.92M | — |
| Current liabilities | 16.16M | 10.24M | 7.47M | 11.29M | — | 13.35M | — |
| Long-term debt | — | — | — | 2.15M | — | — | — |
| Total debt | — | — | — | 2.15M | — | — | — |
| Total liabilities | 16.40M | 10.88M | 8.32M | 12.50M | — | 14.05M | — |
| Shareholders' equity | 57.04M | 82.16M | 124.65M | 102.13M | 123.61M | 130.87M | 161.78M |
| Net debt | — | — | — | -13.27M | — | — | — |
| Cash flow statement | |||||||
| Operating cash flow | — | — | — | — | — | — | — |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.